首页> 外文期刊>Arthritis and Rheumatism >Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.
【24h】

Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.

机译:系统性红斑狼疮患者中IRF5风险单倍型与高血清干扰素-α活性的关联。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: A haplotype of the interferon regulatory factor 5 (IRF5) gene has been associated with the risk of developing systemic lupus erythematosus (SLE), and our previous studies have demonstrated that high levels of serum interferon-alpha (IFNalpha) activity are a heritable risk factor for SLE. The aim of this study was to determine whether the IRF5 SLE risk haplotype mediates the risk of SLE by predisposing patients to the development of high levels of serum IFNalpha activity. METHODS: IFNalpha levels in 199 SLE patients of European and Hispanic ancestry were measured with a sensitive functional reporter cell assay. The rs2004640, rs3807306, rs10488631, and rs2280714 single-nucleotide polymorphisms (SNPs) in IRF5 were genotyped in these patients. Haplotypes were categorized as SLE risk, neutral, or protective based on published data. RESULTS: SLE patients with risk/risk and riskeutral IRF5 genotypes had higher serum IFNalpha activity than did those with protective/protective and neutral/protective genotypes (P = 0.025). This differential effect of IRF5 genotype on serum IFNalpha levels was driven largely by SLE patients who were positive for either anti-RNA binding protein (anti-RBP) or anti-double-stranded DNA (anti-dsDNA) autoantibodies (P = 0.012 for risk/risk or riskeutral versus protective/protective or neutral/protective). The rs3807306 genotype was independently associated with high serum IFNalpha in this autoantibody group. We found no difference in IFNalpha activity according to IRF5 genotype in patients lacking either type of autoantibody or in patients positive for both classes of autoantibody. CONCLUSION: The IRF5 SLE risk haplotype is associated with higher serum IFNalpha activity in SLE patients, and this effect is most prominent in patients positive for either anti-RBP or anti-dsDNA autoantibodies. This study demonstrates the biologic relevance of the SLE risk haplotype of IRF5 at the protein level.
机译:目的:干扰素调节因子5(IRF5)基因的单倍型与发生系统性红斑狼疮(SLE)的风险有关,我们以前的研究表明,高水平的血清干扰素-α(IFNalpha)活性是可遗传的SLE的危险因素。这项研究的目的是通过使患者易患高水平的血清IFNalpha活性来确定IRF5 SLE风险单倍型是否介导SLE风险。方法:采用敏感的功能报告细胞分析法测定了199名欧洲和西班牙裔SLE患者的IFNα水平。在这些患者中对IRF5中的rs2004640,rs3807306,rs10488631和rs2280714单核苷酸多态性(SNP)进行基因分型。根据已发布的数据,单倍型分为SLE风险,中性或保护性。结果:具有风险/风险和风险/中性IRF5基因型的SLE患者的血清IFNα活性高于具有保护/保护性和中性/保护性基因型的SLE患者(P = 0.025)。 IRF5基因型对血清IFNalpha水平的这种差异作用主要是由SLE患者驱动的,这些患者的抗RNA结合蛋白(anti-RBP)或抗双链DNA(anti-dsDNA)自身抗体呈阳性(风险P = 0.012) /风险或风险/中性与保护性/保护性或中性/保护性相比)。在该自身抗体组中,rs3807306基因型与高血清IFNα独立相关。我们发现缺乏IRF5基因型的患者在缺乏两种自身抗体类型的患者或两种自身抗体均为阳性的患者中,IFNα活性没有差异。结论:IRF5 SLE危险单倍型与SLE患者较高的血清IFNalpha活性有关,这种作用在抗RBP或抗dsDNA自身抗体阳性的患者中最为明显。这项研究证明了IRF5的SLE风险单倍型在蛋白质水平上的生物学相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号